Author

E. A. Rozeman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Gangaev· 1 shared A. Ribas· 1 shared A. Shahrabi· 1 shared B. de Bruijn· 1 shared B. Schilling· 1 shared C. Blank· 1 shared C. U. Blank· 1 shared D. J. Adams· 1 shared

Activity by Year

2020-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 20 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Gangaev

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Differential effects of PD-1 and CTLA-4 blockade on the melanoma-reactive CD8 T cell response

A. Gangaev, E. A. Rozeman, M. W. Rohaan, D. Philips, S. Patiwael, J. H. van den Berg, A. Ribas, D. Schadendorf, B. Schilling, T. Shumacher, C. Blank, J. B. A. G. Haanen, P. Kvistborg

The paper shows PD-1 blockade in melanoma patients does not increase the breadth or magnitude of melanoma-reactive CD8 T cells in peripheral blood, suggesting PD-1 acts mainly at the tumor site.

bioRxiv · Dec 15, 2020Immunology

PREDICTIVE IMMUNE CHECKPOINT BLOCKADE CLASSIFIERS DISTINGUISHING MONO- VERSUS COMBINATION THERAPY REQUIREMENT

O. Krijgsman, K. Kemper, J. Boshuizen, D. W. Vredevoogd, E. A. Rozeman, S. Ibanez Molero, B. de Bruijn, P. Cornelissen-Steijger, A. Shahrabi, M. Del Castillo Velasco-Herrera, J.-Y. Song, M. A. Ligtenberg, R. J. C. Kluin, T. Kuilman, P. Ross-MacDonald, , D. S. Peeper

This paper develops two genetic signatures, InTumor and ExTumor, to predict immune checkpoint blockade response in melanoma patients, enabling stratification for monotherapy or combination therapy.

bioRxiv · Jul 14, 2020 · PreprintCancer Biology